Pharmacologic inhibition of COX-1 and COX-2 in influenza A viral infection in mice.

PloS One
Michelle A CareyDori R Germolec

Abstract

We previously demonstrated that cyclooxygenase (COX)-1 deficiency results in greater morbidity and inflammation, whereas COX-2 deficiency leads to reduced morbidity, inflammation and mortality in influenza infected mice. We investigated the effects of COX-1 and COX-2 inhibitors in influenza A viral infection. Mice were given a COX-1 inhibitor (SC-560), a COX-2 inhibitor (celecoxib) or no inhibitor beginning 2 weeks prior to influenza A viral infection (200 PFU) and throughout the course of the experiment. Body weight and temperature were measured daily as indicators of morbidity. Animals were sacrificed on days 1 and 4 post-infection and bronchoalveolar lavage (BAL) fluid was collected or daily mortality was recorded up to 2 weeks post-infection. Treatment with SC-560 significantly increased mortality and was associated with profound hypothermia and greater weight loss compared to celecoxib or control groups. On day 4 of infection, BAL fluid cells were modestly elevated in celecoxib treated mice compared to SC-560 or control groups. Viral titres were similar between treatment groups. Levels of TNF-alpha and G-CSF were significantly attenuated in the SC-560 and celecoxib groups versus control and IL-6 levels were significantly l...Continue Reading

References

Jun 7, 1994·Proceedings of the National Academy of Sciences of the United States of America·E StanleyA R Dunn
May 20, 1999·The Journal of Clinical Investigation·B RoccaG A FitzGerald
Sep 1, 1999·Proceedings of the National Academy of Sciences of the United States of America·H HizakiA Ichikawa
Sep 16, 1999·Biochemical Pharmacology·R LangenbachH Tiano
Jul 4, 2001·The Journal of Clinical Investigation·S L TilleyB H Koller
Oct 20, 2001·FASEB Journal : Official Publication of the Federation of American Societies for Experimental Biology·I TegederG Geisslinger
Apr 17, 2002·American Journal of Respiratory and Critical Care Medicine·R Stokes PeeblesJames R Sheller
May 16, 2002·International Immunopharmacology·Bianca Rocca, Garret A FitzGerald
Mar 11, 2003·American Journal of Respiratory and Critical Care Medicine·Michelle A CareyDarryl C Zeldin
Aug 5, 2003·Prostaglandins, Leukotrienes, and Essential Fatty Acids·Michelle A CareyDarryl C Zeldin
Dec 9, 2003·Mechanisms of Ageing and Development·Hiroshi SaitoB Mark Evers
Feb 24, 2004·Frontiers in Bioscience : a Journal and Virtual Library·Lisa R Leon
May 1, 2004·FASEB Journal : Official Publication of the Federation of American Societies for Experimental Biology·Timothy D Warner, Jane A Mitchell
Jun 22, 2005·Prostaglandins & Other Lipid Mediators·Kirsi NarkoTimothy Hla
Nov 8, 2005·The Journal of Immunology : Official Journal of the American Association of Immunologists·Michelle A CareyDori R Germolec
Nov 14, 2006·Brain, Behavior, and Immunity·Tim R TraynorJames M Krueger
Feb 3, 2007·American Journal of Physiology. Regulatory, Integrative and Comparative Physiology·Eyup S Akarsu, Soner Mamuk
Aug 28, 2007·Vaccine·F Carrat, A Flahault
Jan 29, 2008·Recent Patents on Anti-infective Drug Discovery·Edward G Saravolac, Jonathan P Wong
Apr 19, 2008·The Lancet Infectious Diseases·David S Fedson
Jun 3, 2009·Cleveland Clinic Journal of Medicine·Sherif Beniameen Mossad
Jun 12, 2009·American Journal of Physiology. Regulatory, Integrative and Comparative Physiology·Alexandre A SteinerAndrej A Romanovsky
May 23, 2012·American Journal of Alzheimer's Disease and Other Dementias·Zhen TangZhengwan Qu

❮ Previous
Next ❯

Citations

Mar 29, 2014·Shock·Ulrike NieslerMarkus S Huber-Lang
Nov 29, 2014·BMC Infectious Diseases·Theodoros KelesidisSotirios Tsiodras
Jun 6, 2012·Mediators of Inflammation·Mary K McCarthy, Jason B Weinberg
Aug 4, 2011·Expert Review of Anti-infective Therapy·Ilyse DarwishW Conrad Liles
Oct 2, 2014·Expert Review of Anti-infective Therapy·François Coulombe, Maziar Divangahi
Dec 27, 2011·Trends in Pharmacological Sciences·Konstantin H MüllerDenis E Kainov
Jul 21, 2015·Cellular & Molecular Immunology·Qiang LiuZhan-qiu Yang
Jul 30, 2011·Antiviral Research·Suki M Y LeeJ S M Peiris
Nov 15, 2013·Influenza and Other Respiratory Viruses·David S C Hui, Nelson Lee
Jan 4, 2013·Influenza and Other Respiratory Viruses·Frederick G Hayden
Nov 1, 2016·Expert Review of Clinical Pharmacology·Aisling Mc Mahon, Ignacio Martin-Loeches
Nov 13, 2013·Innate Immunity·Shweta TripathiKevan L Hartshorn
Jun 7, 2016·Scientific Reports·Sabine Eva DudekChristina Ehrhardt
May 14, 2016·World Journal of Virology·Carlos A Guerrero, Orlando Acosta
Aug 24, 2011·Antiviral Chemistry & Chemotherapy·Kurumi YazawaTsugiya Murayama
Jan 4, 2013·Clinical and Vaccine Immunology : CVI·Riccardo V D'EliaGraeme C Clark
Mar 7, 2012·Microbiology and Molecular Biology Reviews : MMBR·Jennifer R TisoncikMichael G Katze
Apr 5, 2015·American Journal of Physiology. Lung Cellular and Molecular Physiology·Parker S WoodsIan C Davis
Sep 27, 2018·Frontiers in Immunology·Sophia Davidson
May 23, 2020·Nutrients·Ioannis ZabetakisAlexandros Tsoupras
Jan 10, 2021·Biomedicine & Pharmacotherapy = Biomédecine & Pharmacothérapie·Esmé Jansen van VurenBrian H Harvey
Oct 6, 2020·Cardiology in Review·Daniel ZhaoWilliam Frishman
Oct 3, 2020·International Journal of Infectious Diseases : IJID : Official Publication of the International Society for Infectious Diseases·Semih BaghakiErsin Yavuz
Aug 7, 2021·Critical Reviews in Microbiology·Fanhua WeiYujiong Wang
Oct 1, 2021·The Journal of Clinical Investigation·Hong LiDarryl C Zeldin

❮ Previous
Next ❯

Software Mentioned

GraphPad
GraphPad Prism

Related Concepts

Related Feeds

Antivirals

Antivirals are medications that are used specifically for treating viral infections. Discover the latest research on antivirals here.

Candidiasis

Candidiasis is a common fungal infection caused by Candida and it can affect many parts for the body including mucosal membranes as well as the gastrointestinal, urinary, and respiratory tracts. Here is the latest research.

Candidiasis (ASM)

Candidiasis is a common fungal infection caused by Candida and it can affect many parts for the body including mucosal membranes as well as the gastrointestinal, urinary, and respiratory tracts. Here is the latest research.

Anti-inflammatory Treatments

A drug or substance that reduces inflammation (redness, swelling, and pain) in the body. Anti-inflammatory agents block certain substances in the body that cause inflammation and swelling. Discover the latest research on anti-inflammatory treatments here

Antivirals (ASM)

Antivirals are medications that are used specifically for treating viral infections. Discover the latest research on antivirals here.

Candida albicans

Candida albicans is an opportunistic, fungal pathogen of humans that frequently causes superficial infections of oral and vaginal mucosal surfaces of debilitated and susceptible individuals. Discover the latest research on Candida albicans here.